Fernando Arevalo, MD PhD

J. Fernando Arevalo, a holder of MD, and PhD degrees, completed his medical and ophthalmology training in Caracas, Venezuela (his native country), before traveling to Bogota, Colombia for a two-year Retina and Vitreous fellowship. After this intensive training, he traveled to the USA for a 2-year Retina and Vitreous/Uveitis and Intraocular Inflammation fellowship at UCSD. The following year, Dr. Arevalo went to Philadelphia for an Ocular Oncology fellowship at Wills Eye Hospital. After a successful career in Venezuela for 15 years, Dr. Arevalo was invited by Johns Hopkins University in Baltimore to work as a Professor of Ophthalmology and the Chief of the Retina Division of the King Khaled Eye Hospital (KKESH) in Riyadh, Saudi Arabia for a four-year tenure, followed by an appointment at the Wilmer Eye Institute as the Edmund F. and Virginia B. Ball Professor of Ophthalmology in the Retina Division, and an appointment as chief of ophthalmology at Johns Hopkins Bayview Medical Center in 2015. As a clinical scientist, Dr. Arevalo has more than 900 (400 in MEDLINE) scientific publications, 18 books, and more than 1500 invited lecture presentations that have led to international recognition and awards including the Macula Society Gass Medal, the Pan-American Association of Ophthalmology Life & Legacy Award, and the American Academy of Ophthalmology Life Achievement Award, and Distinguished Services Award, and the WOC Gonin Medal. Dr. Arevalo is a former President of the Pan-American Retina and Vitreous Society (2006-2008), Past-President (2017-2019) of the Pan-American Association of Ophthalmology, and immediate Past-chairman (2021-2024) of the Pan-American Ophthalmological Foundation.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:GENENTECHTopic:Anti-VEGFDate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Topcon Medical Systems IncTopic:ImagingDate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:EyePoint PharmaceuticalsTopic:TKIsDate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Alimera Sciences, IncTopic:IluvienDate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AstellasTopic:GADate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Apellis PharmaceuticalsTopic:GADate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Belite Bio, IncTopic:GADate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:NeoVascularX, IncTopic:Anti-VEGFDate added:04/01/2026Date updated:04/01/2026Relationship end date:04/01/2026

Facebook
X
LinkedIn
Forward